An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227). Issue 2 (December 2015) - Hellmann, Matthew; Ramalingam, Suresh; Reck, Martin; O'Byrne, Ken; Paz-Ares, Luis; Harbison, Christopher; Bhagavatheeswaran, Prabhu; Nathan, Faith; Brahmer, Julie